Thermo Fisher Scientific 株価情報 (NYSE: TMO)

最新ニュース Thermo Fisher Scientific (NYSE:TMO) 株価情報

Thermo Fisher Scientific

Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of mid-2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (22%); and lab products and services, which includes CRO services (54%).

Thermo Fisher Scientific Inc Common Stock

Thermo Fisher Scientific Inc

TomTom NV

TOMOE ENGINEERING CO by Tomoe Engineering Co. Ltd.

Trimol Group Inc

Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) has outperformed the market over the past 15 years by 6.03% on an annualized basis producing an average annual return of 17.98%. Currently, Thermo Fisher Scientific has a market capitalization of $214.32 billion. 
Buying $100 In TMO: If an investor had bought $100 of TMO stock 15 years ago, it would be worth $1,195.73 today based on a price of $561.47 for TMO at the time of writing.
<h3>Thermo Fisher Scientific's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737125108_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

$100 Invested In Thermo Fisher Scientific 15 Years Ago Would Be Worth This Much Today

Morgan Stanley analyst Tejas Savant maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Overweight and lowers the price target from $670 to $647.

Price Target

Analyst Ratings

Morgan Stanley Maintains Overweight on Thermo Fisher Scientific, Lowers Price Target to $647

Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) has outperformed the market over the past 20 years by 7.25% on an annualized basis producing an average annual return of 15.55%. Currently, Thermo Fisher Scientific has a market capitalization of $198.58 billion. 
Buying $100 In TMO: If an investor had bought $100 of TMO stock 20 years ago, it would be worth $1,805.10 today based on a price of $520.23 for TMO at the time of writing.
<h3>Thermo Fisher Scientific's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1735770610_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Thermo Fisher Scientific Stock In The Last 20 Years

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Scotiabank analyst Sung Ji Nam initiated coverage on Thermo Fisher Scientific Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Sector Perform rating and announced a price target of $605. Thermo Fisher Scientific shares closed at $524.05 on Friday. <a href="https://www.benzinga.com/quote/TMO/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Goldman Sachs analyst Allen Chang initiated coverage on Pony AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) with a Buy rating and announced a price target of $19.6. Pony AI shares closed at $13.16 on Friday. See how other analysts view this stock.</li>
<li>Compass Point analyst Dominick Gabriele initiated coverage on NCR Atleos Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NATL#NYSE">NATL</a>) with a Buy rating and announced a price target of $57. NCR Atleos shares closed at $32.33 on Friday. <a href="https://www.benzinga.com/quote/NATL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>D. Boral Capital analyst Jason Kolbert initiated coverage on Omeros Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) with a Buy rating and announced a price target of $36. Omeros shares closed at $10.31 on Friday. <a href="https://www.benzinga.com/quote/OMER/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Alliance Global Partners analyst Aaron Grey initiated coverage on Worksport Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKSP#NASDAQ">WKSP</a>) with a Buy rating and announced a price target of $2. Worksport shares closed at $0.8465 on Thursday. <a href="https://www.benzinga.com/quote/WKSP/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying OMER stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="573" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23103558/image-192-1024x573.png" alt="" class="wp-image-704444" style="width:622px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23103558/image-192-1024x573.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23103558/image-192-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23103558/image-192-768x430.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23103558/image-192.png 1102w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a></li>
</ul>

Initiation

Markets

NATL

OMER

PONY

WKSP

This Omeros Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Scotiabank analyst Sung Ji Nam initiates coverage on Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Sector Perform rating and announces Price Target of $605.

Scotiabank Initiates Coverage On Thermo Fisher Scientific with Sector Perform Rating, Announces Price Target of $605

Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) has outperformed the market over the past 10 years by 3.93% on an annualized basis producing an average annual return of 15.26%. Currently, Thermo Fisher Scientific has a market capitalization of $200.40 billion. 
Buying $1000 In TMO: If an investor had bought $1000 of TMO stock 10 years ago, it would be worth $4,225.50 today based on a price of $525.00 for TMO at the time of writing.
<h3>Thermo Fisher Scientific's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734123590_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Thermo Fisher Scientific Stock In The Last 10 Years

B of A Securities analyst Derik De Bruin maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Buy and lowers the price target from $675 to $660.

B of A Securities Maintains Buy on Thermo Fisher Scientific, Lowers Price Target to $660

Mainz Biomed N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYNZ#NASDAQ">MYNZ</a>) announced a 1-for-40 <a href="https://www.benzinga.com/pressreleases/24/11/g42243811/mainz-biomed-announces-stock-split" target="_blank" rel="noreferrer noopener">reverse stock split</a>, effective Dec. 3. The company specializes in the early detection of cancer.
Last month, Mainz Biomed reported a collaborative agreement with Thermo Fisher Scientific Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) through its subsidiary Life Technologies Corporation.
The collaboration agreement will enable Mainz Biomed and Thermo Fisher to jointly develop and potentially commercialize Mainz Biomed&#8217;s Next Generation colorectal <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41900924/mainz-biomed-and-thermo-fisher-scientific-sign-a-collaboration-agreement-for-the-development-of-ne" rel="noreferrer noopener">cancer screening product</a>.
The collaboration will harness Thermo Fisher&#8217;s technologies, instrumentation and information translation systems to enable Mainz Biomed to develop proprietary assays for its mRNA-based next-generation colorectal cancer screening tests.
Mainz Biomed&#8217;s flagship non-invasive test targets the early detection of colorectal cancer and focuses on precancerous lesions, particularly advanced adenomas.
The collaboration will leverage combined capabilities to deliver testing solutions being developed at Mainz Biomed&#8217;s laboratories in Mainz, Germany.
Guido Baechler, CEO of Mainz Biomed, said: &#8220;This collaboration with Thermo Fisher will be instrumental to our goal to bring to market a home collection colorectal screening tool with highly effective detection of adenomas.&#8221;
In October, Mainz Biomed reported a 4% increase in revenue and a 32% decrease in operational losses for the first half of 2024. These decreases result from the company&#8217;s efforts to reduce costs during the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/g41425438/mainz-biomed-reports-mid-year-2024-financial-results-and-provides-corporate-update" rel="noreferrer noopener">first half of the year</a>.
The company announced significant improvements to its ColoAlert&nbsp;product, which is available across Europe and in select international markets.
The company says that the new proprietary buffer used in ColoAlert&nbsp;significantly reduces the necessity for additional sample submissions, thereby decreasing how long it takes patients to obtain their results.
This enhancement enabled ColoAlert&nbsp;to achieve the industry&#8217;s lowest retesting rates, ensuring that screening outcomes are delivered within two to three days of arrival at the laboratory.
Price Action: MYNZ stock is down 13.09% at $6.93 at publication Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42296768/blackrock-makes-12-billion-power-move-acquires-hps-to-bolster-private-credit-offerings" target="_blank" rel="noreferrer noopener">BlackRock Makes $12 Billion Power Move &#8211; Agrees To Acquire HPS To Bolster Private Credit Offerings</a></li>
</ul>
Photo: Shutterstock

Large Cap

Health Care

Contracts

Stock Split

Movers

General

MYNZ

Mainz Biomed Announces Reverse Stock Split Soon After Collaborating With MedTech Giant Thermo Fisher Scientific

Thermo Fisher Scientific's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) short percent of float has risen 10.39% since its last report. The company recently reported that it has 3.23 million shares sold short, which is 0.85% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.99 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Thermo Fisher Scientific Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732901421_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Thermo Fisher Scientific has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Thermo Fisher Scientific's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Thermo Fisher Scientific's peer group average for short interest as a percentage of float is 4.79%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Thermo Fisher Scientific?

Thermo Fisher Scientific Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), the world leader in serving science, today announced that its Board of Directors has authorized the repurchase of $4 billion of shares of its common stock in the open market or in negotiated transactions. The authorization has no expiration date. This replaces the company's existing repurchase authorization, of which $1 billion was remaining.

Buybacks

Thermo Fisher Scientific Authorizes $4B Of Share Repurchases; Replaces The Company's Existing Repurchase Authorization, Of Which $1B Was Remaining

Financial giants have made a conspicuous bullish move on Thermo Fisher Scientific. Our analysis of options history for Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) revealed 12 unusual trades.
Delving into the details, we found 41% of traders were bullish, while 33% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $638,204, and 6 were calls, valued at $1,331,814.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $520.0 to $610.0 for Thermo Fisher Scientific during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Thermo Fisher Scientific's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Thermo Fisher Scientific's whale activity within a strike price range from $520.0 to $610.0 in the last 30 days. 
<h3>Thermo Fisher Scientific Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731614512_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TMO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$98.2</td>
<td>$98.0</td>
<td>$98.0</td>
<td>$540.00</td>
<td>$588.0K</td>
<td align="right">3</td>
<td align="right">101</td>
</tr>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$77.1</td>
<td>$71.2</td>
<td>$77.1</td>
<td>$610.00</td>
<td>$308.4K</td>
<td align="right">40</td>
<td align="right">52</td>
</tr>
<tr>
<td>TMO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$98.4</td>
<td>$91.0</td>
<td>$98.4</td>
<td>$540.00</td>
<td>$196.8K</td>
<td align="right">3</td>
<td align="right">40</td>
</tr>
<tr>
<td>TMO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$98.1</td>
<td>$98.1</td>
<td>$98.1</td>
<td>$540.00</td>
<td>$196.2K</td>
<td align="right">3</td>
<td align="right">135</td>
</tr>
<tr>
<td>TMO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$98.4</td>
<td>$98.5</td>
<td>$98.5</td>
<td>$540.00</td>
<td>$187.1K</td>
<td align="right">3</td>
<td align="right">19</td>
</tr>
</tbody>
</table>

<h3>About Thermo Fisher Scientific</h3>
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of mid-2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (22%); and lab products and services, which includes CRO services (54%).
Following our analysis of the options activities associated with Thermo Fisher Scientific, we pivot to a closer look at the company's own performance.
<h3>Thermo Fisher Scientific's Current Market Status</h3>
<ul>
<li>Trading volume stands at 1,042,301, with TMO's price down by -0.94%, positioned at $536.79.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 76 days.</li>
</ul>
<h3>Expert Opinions on Thermo Fisher Scientific</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $647.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Stifel persists with their Buy rating on Thermo Fisher Scientific, maintaining a target price of $665. 
&#x2A; Consistent in their evaluation, an analyst from RBC Capital keeps a Outperform rating on Thermo Fisher Scientific with a target price of $718. 
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Equal-Weight rating for Thermo Fisher Scientific, targeting a price of $610. 
&#x2A; Consistent in their evaluation, an analyst from Evercore ISI Group keeps a Outperform rating on Thermo Fisher Scientific with a target price of $620. 
&#x2A; Maintaining their stance, an analyst from Baird continues to hold a Outperform rating for Thermo Fisher Scientific, targeting a price of $622. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Thermo Fisher Scientific, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Check Out What Whales Are Doing With TMO

With the downfall of Covid-19, pharmaceutical companies turned to oncology in search for their next growth story. Earlier in October, Pfizer Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pfe#NYSE">PFE</a>) reported its third quarter revenue grew&nbsp;14% on an operational basis&nbsp;due to approved cancer products from Seagen it acquired last December. On the other hand, Moderna Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrna#NASDAQ">MRNA</a>) posted a surprise profit and higher than expected revenue following the launch of its updated Covid-19 vaccine earlier this year as focused on slashing costs. But, even with Covid-19 still lingering in the air, Moderna has also focused on harnessing the power of mRNA to make biotech history by revolutionizing cancer treatment. However, there is also a significant advancement in early screening and even possible prevention when it comes to the cancer front. For example, their much smaller peer,&nbsp;Mainz Biomed (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mynz#NASDAQ">MYNZ</a>) just announced a new collaboration agreement aimed at developing and potentially commercializing its next generation colorectal cancer screening product.
Mainz Biomed&rsquo;s next generation CRC screening product is coming to redefine standards.
Mainz Biomed is a molecular genetics diagnostic company specialized in the early detection of cancer. This week, it announced it entered into a collaborative agreement with Thermo Fisher Scientific Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tmo#NYSE">TMO</a>), through its subsidiary Life Technologies Corporation, a leading provider of life sciences solutions and services.
With the power of Thermo Fisher&rsquo;s powerful technologies, instrumentation and information translation systems, Mainz Biomed will be empowered to develop the proprietary assays for its mRNA-based next-generation CRC screening tests which are raising the bar when it comes to early cancer detection. With U.S. and European clinical trials of its flagship non-invasive test, Mainz Biomed promises to redefine standards in cancer screening. With ColoAlert, Mainz Biomed not only offers the early detection of colorectal cancer but also detects advanced adenomas which are a known cancer precursor, therefore, opening the doors its peers didn&rsquo;t dare to tackle, the ones of cancer prevention.&nbsp;
Pfizer topped estimates and hiked its full year guidance.&nbsp;
Cancer drugs brought in $854 million to Pfizer&rsquo;s revenue table, including $409 million from a targeted treatment for bladder cancer called Padcev and $268 million from lymphoma-targeting Adectris. Good results provided some much-needed good news for Pfizer CEO Albert Bourla, who is facing new pressure from activist investor Starboard Value.
For the third quarter, Pfizer reported overall revenue of &nbsp;$17.7 billion.
Moderna continues to focus on developing cancer treatment along with lowering costs.
Back in September, Moderna revealed its plan to cut its research and development budget by $1.1 billion over the next three years while it aims to get FDA approval for 10 products like cancer treatments and vaccines. During the latest earnings call, Moderna CEO St&eacute;phane Bancel was pleased with the cost efficiency achieved during the quarter, with the progress being even better than planned. For the third quarter, Moderna reported revenue of&nbsp;$1.86 billion, smashing LSEG&rsquo;s consensus estimate of $1.25 billion. While Pfizer already counts on oncology for boosting sales, Moderna&rsquo;s sales are still made by the Covid shot, along with RSV one that brought&nbsp;&nbsp;$10 million in U.S. sales after gaining approval in May. However, with 45 products in development powered by its messenger RNA platform, Moderna expects to bring 10 of them to the market over the next three years.
DISCLAIMER: This content is for informational purposes only. It is not intended as investing advice.
This article is from an unpaid external contributor. It does not represent Benzinga&#39;s reporting and has not been edited for content or accuracy.

Penny Stocks

MRNA

The Oncology Bet Is Already Paying Off For Pfizer

Mainz Biomed Partners With Thermo Fisher Scientific To Develop Next-Gen Colorectal Cancer Screening Product, Focusing On Early Detection And Advanced Adenoma Identification

Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) has outperformed the market over the past 15 years by 6.7% on an annualized basis producing an average annual return of 18.36%. Currently, Thermo Fisher Scientific has a market capitalization of $212.03 billion. 
Buying $100 In TMO: If an investor had bought $100 of TMO stock 15 years ago, it would be worth $1,242.44 today based on a price of $555.47 for TMO at the time of writing.
<h3>Thermo Fisher Scientific's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730836834_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Thermo Fisher Scientific 15 Years Ago Would Be Worth Today

Investors with a lot of money to spend have taken a bullish stance on Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether this is an institution or just a wealthy individual, we don't know. But when something this big happens with TMO, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 14 options trades for Thermo Fisher Scientific.
This isn't normal.
The overall sentiment of these big-money traders is split between 50% bullish and 21%, bearish.
Out of all of the options we uncovered, 13 are puts, for a total amount of $444,315, and there was 1 call, for a total amount of $35,800.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $520.0 and $570.0 for Thermo Fisher Scientific, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Thermo Fisher Scientific's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Thermo Fisher Scientific's whale trades within a strike price range from $520.0 to $570.0 in the last 30 days. 
<h3>Thermo Fisher Scientific Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730139332_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$8.9</td>
<td>$8.3</td>
<td>$8.05</td>
<td>$530.00</td>
<td>$72.4K</td>
<td style="text-align: right;">201</td>
<td style="text-align: right;">121</td>
</tr>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$8.2</td>
<td>$8.0</td>
<td>$8.13</td>
<td>$530.00</td>
<td>$49.5K</td>
<td style="text-align: right;">201</td>
<td style="text-align: right;">264</td>
</tr>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$8.2</td>
<td>$8.1</td>
<td>$8.08</td>
<td>$530.00</td>
<td>$41.2K</td>
<td style="text-align: right;">201</td>
<td style="text-align: right;">398</td>
</tr>
<tr>
<td>TMO</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$72.8</td>
<td>$70.4</td>
<td>$71.6</td>
<td>$550.00</td>
<td>$35.8K</td>
<td style="text-align: right;">11</td>
<td style="text-align: right;">5</td>
</tr>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/08/24</td>
<td>$11.6</td>
<td>$9.5</td>
<td>$10.48</td>
<td>$560.00</td>
<td>$31.5K</td>
<td style="text-align: right;">79</td>
<td style="text-align: right;">30</td>
</tr>
</tbody>
</table>

<h3>About Thermo Fisher Scientific</h3>
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of end-2023 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (10%); life science solutions (23%); and lab products and services, which includes CRO services (54%).
In light of the recent options history for Thermo Fisher Scientific, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Thermo Fisher Scientific's Current Market Status</h3>
<ul>
<li>Trading volume stands at 472,526, with TMO's price down by -0.34%, positioned at $552.47.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 93 days.</li>
</ul>
<h3>Professional Analyst Ratings for Thermo Fisher Scientific</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $637.4.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Barclays has decided to maintain their Equal-Weight rating on Thermo Fisher Scientific, which currently sits at a price target of $610. 
&#x2A; Maintaining their stance, an analyst from Evercore ISI Group continues to hold a Outperform rating for Thermo Fisher Scientific, targeting a price of $630. 
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Overweight rating on Thermo Fisher Scientific with a target price of $660. 
&#x2A; An analyst from Stifel has decided to maintain their Buy rating on Thermo Fisher Scientific, which currently sits at a price target of $665. 
&#x2A; Maintaining their stance, an analyst from Baird continues to hold a Outperform rating for Thermo Fisher Scientific, targeting a price of $622. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Thermo Fisher Scientific, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Market Whales and Their Recent Bets on TMO Options

Bernstein analyst Eve Burstein maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Market Perform and lowers the price target from $625 to $620.

Bernstein Maintains Market Perform on Thermo Fisher Scientific, Lowers Price Target to $620

RBC Capital analyst Conor McNamara maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Outperform and lowers the price target from $767 to $718.

RBC Capital Maintains Outperform on Thermo Fisher Scientific, Lowers Price Target to $718

WIIM

Thermo Fisher Scientific shares are trading lower after multiple firms lowered their respective price targets on the stock.

Stifel analyst Daniel Arias maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Buy and lowers the price target from $680 to $665.

Stifel Maintains Buy on Thermo Fisher Scientific, Lowers Price Target to $665

Evercore ISI Group analyst Vijay Kumar maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Outperform and lowers the price target from $630 to $620.

Evercore ISI Group Maintains Outperform on Thermo Fisher Scientific, Lowers Price Target to $620

Bernstein upgraded Thermo Fisher (TMO) to Outperform from Market Perform with a $630 price target While the setup in 2025 for U.S. Life Science Too...

Thermo Fisher upgraded to Outperform from Market Perform at Bernstein

Dividend Champion, Contender, And Challenger Highlights: Week Of January 12

Morgan Stanley analyst Tejas Savant maintained a Buy rating on Thermo Fisher (TMO – Research Report) today and set a price target of $647.00. The c...

Morgan Stanley Remains a Buy on Thermo Fisher (TMO)

In a report released on January 10, Conor McNamara from RBC Capital maintained a Buy rating on Thermo Fisher (TMO – Research Report), with a price ...

RBC Capital Remains a Buy on Thermo Fisher (TMO)

Franklin DynaTech Fund Q4 2024 Commentary

Thermo Fisher Scientific Inc. (TMO) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)

ClearBridge Large Cap Growth Fund Q4 2024 Commentary

The U.S. Commerce Department is rolling out new export controls on biotechnology equipment and related technology amid national security concerns l...

U.S. places new export controls on biotech equipment, Reuters reports

U.S. commerce dept. sets export controls on certain lab instruments

Tempering Positive Sentiment Of AI In Biotech

AAPL

ABBV

ABNB

ALRS

AMGN

AMZN

APOG

ASML

AVGO

AXON

BANF

BCPC

BRKR

CHCO

CINF

CTRE

CUBE

EPRT

FCPT

FFMR

FITB

FMAO

FNLC

FULT

FUNC

GILD

GOOG

GOOGL

GWRS

HUBS

IBCP

IIPR

ILMN

INTU

INVH

KLAC

LECO

LRCX

MDLZ

MGRC

MPWR

MSFT

NDSN

NFLX

NVDA

NVSEF

NWFL

PANW

PPTDF

RBCAA

REXR

RGCO

RGLD

RPRX

RVTY

RXRX

STAG

TCGGY

TCHBF

TECH

TFII

THFF

TOWN

TSLA

WDFC

YORW

Screenshot 2024-12-19 at 7.13.05 PM

Biotech

Quest Diagnostics (NYSE: DGX) And Mainz Biomed (NASDAQ: MYNZ) Team Up To Commercialize ColoAlert Early Cancer Detection Screening In The U.S.

Screenshot 2024-11-21 at 6.41.48 PM

Mainz Biomed Inks Major Deal To Develop A Next-Generation Cancer Test

Screenshot 2024-11-12 at 8.43.58 PM

Healthcare Giant Thermo Fisher Scientific Inc. (NYSE: TMO) Inks Deal With Mainz Biomed (NASDAQ: MYNZ) To Develop And Commercialize Next Gen Colorectal Cancer Screening

Press Releases

Thermo Fisher Scientific to Present at the Wolfe 2024 Healthcare Conference on November 19, 2024

Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets

Thermo Fisher Scientific Authorizes $4 Billion of Share Repurchases

Thermo Fisher Scientific Completes $1B Share Repurchase

Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, January 30, 2025

Thermo Fisher Scientific to Present at 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025

Thermo Fisher Scientific's Olink Platform Selected for World's Largest Human Proteome Study

Agilent Technologies

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solns

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Thermo Fisher Scientific

ニュース

最新ニュース Thermo Fisher Scientific (NYSE:TMO) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル